To the Editor

Abstract

Get full access to this article

View all access options for this article.

References

Verstraete

Bernard

Bory

. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985; 1: 842–7.

TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: Phase I findings. N Engl J Med 1985; 312: 936–6.

Schroder

Biamino

Enz-Rudiger

. Intravenous short-term infusion of streptokinase in acute myocardial infarction. Circulation 1983; 67: 536–48.

Sheehan

. Effect of intravenous thrombolytic therapy on left ventricular function: Report from NHLBI thrombolysis in myocardial infarction (TIMI) trial (abstract). J Am Coll Cardiol 1986; 7: 16A.

Crabbe

Cloninger

. Tissue plasminogen activator: A new thrombolytic agent. Clin Pharm 1987; 6: 373–86.

Tissue plasminogen activator: A new thrombolytic agent (correction). Clin Pharm 1987; 6: 925.

Prescribing information. Streptase. Somerville, NJ: Hoechst-Roussel Pharmaceuticals, 1987.

Prescribing information. Activase. South San Francisco: Genentech, 1987.

Alderman

Jutzy

Berte

. Randomized comparison of intravenous versus intracoronary streptokinase therapy for myocardial infarction. Am J Cardiol 1984; 54: 14–9.

10.

Gruppo Italiano per lo Studio Della Streptochinasi Nell'Infarcto Miocardio (GISSI). Effectiveness of intravenous thrombolytic therapy in acute myocardial infarction. Lancet 1986; 1: 397–401.